Form 4: Emmaus Life Sciences CEO Buys Shares
Insider Transaction (Form 4)
Willis C Lee, CEO and a Director of Emmaus Life Sciences, Inc., purchased 530,767 shares of common stock on May 30, 2025.
Summary
- Open-market purchase: acquired 70,000 Common stock, $0.001 par value at $0.02 ($1,400) on May 30, 2025; holds 229,400 after (Indirect).
- Open-market purchase: acquired 170,000 Common stock, $0.001 par value at $0.01 ($1,700) on August 29, 2025; holds 275,400 after (Indirect).
- Open-market purchase: acquired 46,000 Common stock, $0.001 par value at $0.04 ($1,840) on August 25, 2026; holds 445,400 after (Indirect).
- Open-market purchase: acquired 50,000 Common stock, $0.001 par value at $0.05 ($2,500) on August 27, 2026; holds 495,400 after (Indirect).
- Open-market purchase: acquired 94,767 Common stock, $0.001 par value at $0.06 ($5,686) on August 28, 2026; holds 590,167 after (Indirect).
- Open-market purchase: acquired 100,000 Common stock, $0.001 par value at $0.05 ($5,000) on August 31, 2026; holds 690,167 after (Indirect).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $18,126, committing personal capital to the stock.
Insider Transactions
Willis C Lee — Director, Officer (CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2025-05-30 | Open-market purchase | Common stock, $0.001 par value | 70,000 | $0 | $1.4K | 229,400 |
| 2025-08-29 | Open-market purchase | Common stock, $0.001 par value | 170,000 | $0 | $1.7K | 275,400 |
| 2026-08-25 | Open-market purchase | Common stock, $0.001 par value | 46,000 | $0 | $1.8K | 445,400 |
| 2026-08-27 | Open-market purchase | Common stock, $0.001 par value | 50,000 | $0 | $2.5K | 495,400 |
| 2026-08-28 | Open-market purchase | Common stock, $0.001 par value | 94,767 | $0 | $5.7K | 590,167 |
| 2026-08-31 | Open-market purchase | Common stock, $0.001 par value | 100,000 | $0 | $5.0K | 690,167 |
Key Dates
| Date | Description |
|---|---|
| 2025-05-30 | Open-market purchase (70,000 shares) |
| 2025-08-29 | Open-market purchase (170,000 shares) |
| 2026-08-25 | Open-market purchase (46,000 shares) |
| 2026-08-27 | Open-market purchase (50,000 shares) |
| 2026-08-28 | Open-market purchase (94,767 shares) |
| 2026-08-31 | Open-market purchase (100,000 shares) |
Keywords
insider transaction, Form 4, EMMA, Emmaus Life Sciences, Inc., bullish, Willis C Lee
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.